INFANT FORMULA News & Analysis

Analysts forecasts a2 Milk Company to recover revenue losses in China.

Morningstar has downgraded its valuation for the infant formula maker as it grapples with weak growth.

Poor growth in its Chinese reseller channel and a glut of stock could force a decrease in the fair value estimate for the infant formula maker.

Despite the covid disruptions the speciality dairy producer is set to leverage its strong brand and pricing power, says Adam Fleck.

The infant formula maker remains undervalued after upgrading guidance and reaffirming its clout in the key market of China.

Dual-lister A2 Milk has reported a more than 50 per cent jump in half-year net profit, as the company expanded market share in China despite slowing...

A2 is off to a FY19 flier, lifting its earnings for the first four months of the year while appearing unfazed by the prospect of higher marketing...